bristol myers squibb news

Bristol Myers rises, AbbVie sinks

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy treatment for adults with schizophrenia did not meet the primary endpoint of showing a “statistically significant” improvement when compared with a placebo group.

Business Insider · 3d

Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with

Investopedia on MSN · 3d

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint

Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.Abbvie said the trials did not show a statistically significant improvement in symptoms compared with the placebo group at week 6.

MarketWatch on MSN · 3d

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie shares are down 12.4%. In a statement,

2 Dividend Stocks to Buy Hand Over Fist

The Motley Fool on MSN · 6h

2 Beaten-Down Dividend Stocks to Buy and Hold

2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond yields spiked on Nov. 13 as traders doubted how fast and far the Fed can act dovish given that Trump's policies may boost inflation.

Yahoo · 9h

2 Dividend Stocks to Buy Hand Over Fist in November

The ability to get through challenging periods and continue performing well without resorting to dividend cuts. AbbVie has increased its payouts despite Humira's loss of patent exclusivity. The company is a Dividend King with an active streak of 52 consecutive payout increases.

Barchart on MSN · 7h

2 Energy Dividend Stocks to Buy This November for Growth and Income

As oil prices remain volatile around thelatest OPEC+ moves and ongoing demand concerns, all eyes are on the energy sector, especially as investors consider President-elect Trump’s energy policies. While deregulation could favor the energy sector,

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

17h

Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week

Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

BioSpace16h

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

MarketWatch2d

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to ...

Buy, Sell, Or Hold BMY Stock?

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

What's Going On With Bristol-Myers Squibb Shares Monday?

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Bristol Myers initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...

Fintel on MSN2d

Leerink Partners Upgrades Bristol-Myers Squibb Company - Preferred Security (BMYMP)

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb Company - ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Bristol Myers rises, AbbVie sinks

2 Dividend Stocks to Buy Hand Over Fist

Related topics